Literature DB >> 24849129

Tetracycline- and furazolidone-containing quadruple regimen as rescue treatment for Helicobacter pylori infection: a single center retrospective study.

Yuemiao Zhang1, Wen Gao, Hong Cheng, Xuezhi Zhang, Fulian Hu.   

Abstract

BACKGROUND AND
OBJECTIVE: Eradication rate of Helicobacter pylori decreases worldwide, while antibiotics resistance rates of H. pylori increase rapidly in recent years. In most cases, H. pylori would be resistant to clarithromycin, metronidazole, and quinolone if these antibiotics had been used as component of eradication regimen. H. pylori strains resistant to both tetracycline and furazolidone are rare. The aim of our study was to evaluate efficacy and side effects of tetracycline- and furazolidone-containing quadruple regimen as rescue treatment.
METHODS: Patients with H. pylori infection given RTFB (rabeprazole 20 mg b.i.d. + tetracycline 750 mg b.i.d. +furazolidone 100 mg b.i.d. + colloidal bismuth subcitrate 200 mg b.i.d.) regimen for 14 days as rescue treatment were enrolled in this retrospective study. Eradication status was evaluated by (13) C-urea breath test, and side effects were collected.
RESULTS: One hundred and nine patients were enrolled. The intention-to-treat eradication rate was 91.74% (100 of 109) and 95.24% (100 of 105) per protocol analysis. Side effects including fever, palpitation, and skin rash occurred in 35 patients.
CONCLUSIONS: The 14-day tetracycline- and furazolidone-containing quadruple regimen can achieve a relatively high eradication rate as rescue treatment. Some side effects including fever may occur during the treatment.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  Helicobacter pylori; efficacy; furazolidone; side effects; tetracycline

Mesh:

Substances:

Year:  2014        PMID: 24849129     DOI: 10.1111/hel.12143

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  7 in total

1.  Low efficacy of levofloxacin-doxycycline-based third-line triple therapy for Helicobacter pylori eradication in Italy.

Authors:  Omero Alessandro Paoluzi; Giovanna Del Vecchio Blanco; Emanuela Visconti; Manuela Coppola; Carla Fontana; Marco Favaro; Francesco Pallone
Journal:  World J Gastroenterol       Date:  2015-06-07       Impact factor: 5.742

Review 2.  Mechanisms of Helicobacter pylori antibiotic resistance and molecular testing.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki
Journal:  Front Mol Biosci       Date:  2014-10-24

3.  A randomized, multicenter and noninferiority study of amoxicillin plus berberine vs tetracycline plus furazolidone in quadruple therapy for Helicobacter pylori rescue treatment.

Authors:  Jian Zhang; Chuan Han; Wen Quan Lu; Na Wang; Si Ran Wu; Yong Xi Wang; Jin Ping Ma; Jie Hong Wang; Cheng Hao; Dong Hong Yuan; Na Liu; Yong Quan Shi
Journal:  J Dig Dis       Date:  2020-06-09       Impact factor: 2.325

4.  Two Different 1-Week Quadruple Therapies Given Back-to-Back Consecutive Therapy for Difficult-to-Treat Helicobacter pylori Infection: A Pilot Study.

Authors:  Jing Liu; Chao-Ran Ji; Yue-Yue Li; Chen Qiao; Jun-Nan Hu; Meng Wan; Min-Juan Lin; Bo-Shen Lin; Juan Wang; Jing Zha; Li-Xiang Li; Xiu-Li Zuo
Journal:  Clin Transl Gastroenterol       Date:  2021-08-16       Impact factor: 4.488

5.  Efficacy and safety of high-dose esomeprazole-amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial.

Authors:  Hanxin Bi; Xingxing Chen; Yuxin Chen; Xin Zhao; Shasha Wang; Jiehong Wang; Ting Lyu; Shuang Han; Tao Lin; Mingquan Li; Donghong Yuan; Junye Liu; Yongquan Shi
Journal:  Chin Med J (Engl)       Date:  2022-07-20       Impact factor: 6.133

6.  Treatment with compound Lactobacillus acidophilus followed by a tetracycline- and furazolidone-containing quadruple regimen as a rescue therapy for Helicobacter pylori infection.

Authors:  Airu Liu; Yuxin Wang; Yingxiao Song; Yiqi Du
Journal:  Saudi J Gastroenterol       Date:  2020 Mar-Apr       Impact factor: 2.485

7.  Identifying the best regimen for primary eradication of Helicobacter pylori: analysis of 240 cases.

Authors:  Yao Chen; Qingyi Liu; Fulian Hu; Jizheng Ma
Journal:  Microbiologyopen       Date:  2020-10-07       Impact factor: 3.139

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.